Skip to main content

Short Bowel Syndrome clinical trials at UCSF
2 in progress, 1 open to new patients

  • A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome

    open to all eligible people

    This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for patients with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in patients with SBS. SBS patients treated and not treated with teduglutide will be enrolled.

    San Francisco, California and other locations

  • Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

    Sorry, in progress, not accepting new patients

    Teduglutide is approved for treatment of adults with short bowel syndrome (SBS). The purpose of this study is to evaluate the safety and efficacy of teduglutide in children up to the age of 17 with SBS who are dependent on parenteral support. Subjects may choose whether to receive the study drug or to participate in a standard-of-care arm. All participants who complete the study may be eligible to receive the study drug in a long-term extension study.

    San Francisco, California and other locations